gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
gptkbp:abusePotential
|
can be used in illicit methamphetamine synthesis
|
gptkbp:ATCCode
|
R01BA02
|
gptkbp:bioavailability
|
90-100%
|
gptkbp:brand
|
gptkb:Sudafed
gptkb:Dimetapp
gptkb:Actifed
gptkb:Contac
|
gptkbp:CASNumber
|
90-82-4
|
gptkbp:chemicalFormula
|
C10H15NO
|
gptkbp:contraindication
|
severe hypertension
severe coronary artery disease
concurrent use of MAO inhibitors
|
gptkbp:controlledSubstanceStatus
|
regulated due to use in methamphetamine production
|
gptkbp:discoveredIn
|
1889
|
gptkbp:drugClass
|
decongestant
sympathomimetic
|
gptkbp:eliminationHalfLife
|
4.3-8 hours
|
gptkbp:excretion
|
kidneys
|
gptkbp:firstSynthesized
|
gptkb:Nagayoshi_Nagai
|
gptkbp:foundIn
|
combination cold medications
|
gptkbp:has_stereochemistry
|
gptkb:ephedrine
|
https://www.w3.org/2000/01/rdf-schema#label
|
pseudoephedrine
|
gptkbp:IUPACName
|
(1S,2S)-2-methylamino-1-phenylpropan-1-ol
|
gptkbp:KEGGID
|
D08414
|
gptkbp:legalStatus
|
prescription only (in some countries)
over-the-counter (in some countries)
|
gptkbp:mechanismOfAction
|
alpha-adrenergic receptor agonist
beta-adrenergic receptor agonist
|
gptkbp:meltingPoint
|
119-120°C
|
gptkbp:MeSH_ID
|
D011563
|
gptkbp:metabolism
|
liver
|
gptkbp:molecularWeight
|
165.23 g/mol
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:PubChem_CID
|
7028
CHEMBL1201201
|
gptkbp:relatedTo
|
gptkb:ephedrine
gptkb:phenylephrine
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
headache
nervousness
insomnia
increased blood pressure
|
gptkbp:solubility
|
soluble in water
|
gptkbp:UNII
|
Y6MZ3XLO3S
|
gptkbp:usedFor
|
nasal congestion
allergic rhinitis
sinus congestion
|
gptkbp:bfsParent
|
gptkb:amphetamine
|
gptkbp:bfsLayer
|
6
|